+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Urokinase"

From
From
Investigation Report on China's Urokinase Market, 2019-2023 - Product Thumbnail Image

Investigation Report on China's Urokinase Market, 2019-2023

  • Report
  • August 2019
  • 30 Pages
  • China
From
From
From
From
From
Global and Chinese Urokinase Industry, 2021 Market Research Report - Product Thumbnail Image

Global and Chinese Urokinase Industry, 2021 Market Research Report

  • Report
  • January 2021
  • 140 Pages
  • China, Global
From
Pulmonary Embolism (Cardiovascular) - Drugs In Development, 2021 - Product Thumbnail Image

Pulmonary Embolism (Cardiovascular) - Drugs In Development, 2021

  • Drug Pipelines
  • June 2021
  • 44 Pages
  • Global
From
From
From
From
From
From
From
From
From
Loading Indicator

Urokinase is a type of cardiovascular drug used to treat a variety of conditions, including pulmonary embolism, deep vein thrombosis, and acute myocardial infarction. It is a thrombolytic agent, meaning it works by breaking down blood clots and restoring blood flow to the affected area. Urokinase is administered intravenously and is typically used in combination with other medications. It is also used to prevent the formation of new blood clots. Urokinase is a widely used drug in the cardiovascular market, with a variety of manufacturers offering it in different forms. It is available in both generic and branded versions, with the latter being more expensive. The drug is also available in different concentrations, depending on the patient's needs. Some of the companies in the Urokinase market include Pfizer, Sanofi, Merck, and Bristol-Myers Squibb. Show Less Read more